Little Green Pharma Corrects Omitted Director Shareholding Disclosure

Little Green Pharma Ltd. ( (AU:LGP) ) has issued an update.

Little Green Pharma has corrected previous director interest disclosures after identifying an administrative oversight in notices relating to director and managing director Paul Long. The company said Long’s indirect holding of 351,111 ordinary shares via PFL Green Growth Pty Ltd, where he is sole shareholder and beneficiary, had not been included in his initial and subsequent director interest notices, and confirmed that there have been no transactions in those shares since his appointment in March 2025. LGP has now updated the disclosures to include this indirect stake, stressing that all other information in the earlier notices remains accurate, in a move aimed at reinforcing transparency and compliance around director shareholdings for investors and regulators.

The most recent analyst rating on (AU:LGP) stock is a Buy with a A$0.18 price target. To see the full list of analyst forecasts on Little Green Pharma Ltd. stock, see the AU:LGP Stock Forecast page.

More about Little Green Pharma Ltd.

Little Green Pharma Ltd (ASX:LGP) is a global medicinal cannabis company with vertically integrated operations across Europe and Australia. It produces and supplies a diverse portfolio of cannabis-based medicines through wholesalers, pharmacies, clinics and GPs in Australia and more than a dozen export markets, and also derives revenue from its Health House distribution business. Operating three production facilities in Denmark and Australia, including one of Europe’s largest, LGP is among the top three suppliers in Australia, the largest supplier into France, and a major player in Germany and the UK, giving investors leveraged exposure to growing international demand for medicinal cannabis.

Average Trading Volume: 192,812

Technical Sentiment Signal: Sell

Current Market Cap: A$36.68M

See more data about LGP stock on TipRanks’ Stock Analysis page.